share_log

SonoScape Medical (SZSE:300633) Ascends 9.5% This Week, Taking Three-year Gains to 64%

SonoScape Medical (SZSE:300633) Ascends 9.5% This Week, Taking Three-year Gains to 64%

SonoScape醫療(SZSE:300633)本週上漲9.5%,三年累計收益達64%。
Simply Wall St ·  06/13 20:56

By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. For example, the SonoScape Medical Corp. (SZSE:300633) share price is up 62% in the last three years, clearly besting the market decline of around 25% (not including dividends).

通過購買指數基金,您可以輕鬆地與市場回報大致相匹配。但是,如果您選用的是熟練自己挑選的股票,則可以獲得更高的回報。例如,深圳索諾斯科技股份有限公司(SZSE:300633)的股價在過去三年中上漲了62%,明顯超過了市場下跌25%(不包括分紅派息)。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在過去的一週之內,獲得的強勁收益是否表明了長期回報受到基本面的推動值得關注。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然一些人仍然相信有效市場假說,但已經證明市場是過度反應的動態系統,投資者並不總是理性的。一個不完美但簡單的方法來考慮公司市場看法的變化是比較每股收益(EPS)的變化和股價的波動。

SonoScape Medical became profitable within the last three years. That would generally be considered a positive, so we'd expect the share price to be up.

深圳索諾斯科技股份有限公司在過去三年中已經實現盈利。這通常被認爲是一個積極的跡象,我們預計股價會上漲。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。

earnings-per-share-growth
SZSE:300633 Earnings Per Share Growth June 14th 2024
SZSE:300633每股收益在2024年6月14日增長

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. This free interactive report on SonoScape Medical's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

我們很高興地報告,這位CEO的薪酬要比同樣資本化公司的大多數CEO要適中得多。但是,雖然CEO的薪酬始終值得檢查,但真正重要的問題是該公司是否能夠繼續增長收益。如果您想進一步調查該股票,深圳索諾斯科技股份有限公司的收益,營業收入和現金流的免費互動報告是一個很好的起點。

What About Dividends?

那麼分紅怎麼樣呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, SonoScape Medical's TSR for the last 3 years was 64%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

對於任何給定的股票而言,考慮股東總回報以及股票價格回報都非常重要。雖然股票價格回報僅反映了股票價格的變化,但TSR包括了股息(假定它們被再投資)和任何折價的融資或分拆的利益。可以說,TSR給出了股票所生成的回報更全面的圖景。碰巧的是,深圳索諾斯科技股份有限公司在過去3年中的TSR爲64%,超過了前面提到的股票價格回報。這在很大程度上是其分紅派息的結果!

A Different Perspective

不同的觀點

While the broader market lost about 13% in the twelve months, SonoScape Medical shareholders did even worse, losing 22% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 8% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for SonoScape Medical you should know about.

儘管整個市場在過去的12個月中損失了約13%,但深圳索諾斯科技股份有限公司的股東卻表現得更糟糕,損失了22%(包括分紅)。話雖如此,在一個下跌的市場中,一些股票註定會被超賣。關鍵是要關注基本因素的發展。好處在於,長期股東已經賺了錢,在過去的半個十年中,每年增長8%。如果基本數據繼續表明長期可持續增長,當前的拋售可能值得考慮。我發現長期股票價格是企業績效的代理很有趣。但是,要獲得真正的見解,我們還需要考慮其他信息。例如,考慮風險。每個公司都有風險,我們發現深圳索諾斯科技股份有限公司的1個警告標誌您應該知道。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您願意查看另一家公司-具有潛在更優質財務狀況的公司-則不要錯過這個免費的公司列表,這些公司已經證明他們可以增長收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論